Lumos Diagnostics’ FebriDx to Aid Antimicrobial Stewardship Trial

Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an update.

Lumos Diagnostics has announced that its FebriDx point-of-care test will be used in the University of Wollongong’s OPTIMAS-GP Trial, which aims to reduce unnecessary antibiotic prescribing for respiratory infections in primary care settings. This trial, funded by the Australian Government’s Medical Research Future Fund, will evaluate the feasibility and acceptability of FebriDx in Australian general practice, marking its first formal evaluation in this setting. The initiative is part of a broader effort to combat antimicrobial resistance by promoting evidence-based clinical decisions, and Lumos will provide approximately 2,000 test kits at a reduced cost.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

Average Trading Volume: 1,213,628

Technical Sentiment Signal: Sell

Current Market Cap: A$22.46M

For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.